Tiziana Life announces immunologic analysis of nasal foralumab in AD patients

Tiziana Life Sciences (TLSA) announced compelling immunologic findings from the treatment of a moderate Alzheimer’s Disease, AD, patient with intranasal foralumab. Transcriptional analysis of white blood cells before and after foralumab therapy revealed immune modulatory effects. Significant changes were observed in CD4 cells, CD8 cells, and monocytes, underscoring the broad impact of nasal foralumab on immune cell profiles. These results are consistent with improvement in microglia PET scans conducted at the time of immune analysis which demonstrated a marked reduction in inflammation following nasal foralumab showing a link between immune effects and resolution of brain inflammation. In an unexpected discovery, the analysis revealed an increase in phagocytosis markers in classical monocytes, suggesting that nasal foralumab may enhance their ability to clear amyloid plaques. This unexpected effect may open new avenues for treating Alzheimer’s Disease by targeting both inflammation and amyloid accumulation.